No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
GRAL240719P17500
- 1.25
- +1.15+1150.00%
15min DelayClose Jul 19 15:58 ET
1.25High1.05Low
1.10Open0.10Pre Close6 Volume95 Open Interest17.50Strike Price655.00Turnover648.85%IV1.99%PremiumJul 19, 2024Expiry Date0.92Intrinsic Value100Multiplier-2DDays to Expiry0.33Extrinsic Value100Contract SizeAmericanOptions Type-0.7844Delta0.2681Gamma15.79Leverage Ratio-4.2815Theta0.0000Rho-12.39Eff Leverage0.0005Vega
Intraday
- 5D
- Daily
News
The Race to Develop the 'Holy Grail' of Weight-loss Drugs
Stock Warnings: Sunpower, Domino's, and Grail
Grail Announces First Patients Enrolled in REACH Cancer Trial
Express News | GRAIL Shares Are Trading Lower. The Company Announced That the First Participant Has Been Enrolled in the REACH/Galleri-Medicare Study at Community Health Network
Express News | Grail Inc - Medicare to Cover Costs for Galleri Study Participants
Express News | Grail Announces First Participant Enrolled in Reach Study Evaluating Clinical Impact of Galleri® Multi-Cancer Early Detection (Mced) Test in the Medicare Population
Comments
$Grail(GRAL.US$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
1
$Illumina(ILMN.US$ botched the acquisition of $Grail(GRAL.US$ after the move was banned by european authorities and has finished divesting as GRAL just opened shop on stock markets very recently as a separate entity from ILMN. with this shareholders might start to pour money back into Illumina which is clearly undervalued by any metric you throw at it it's not a dead business so there's some money to be made here you can look at the chart recently ...
5
$Grail(GRAL.US$ why circuit breaker?
Read more